Marksans Pharma Gains as UK Subsidiary Secures MHRA Approval for Baclofen 10 mg Tablets

Marksans Pharma Ltd shares gained 2.18% after its wholly owned UK subsidiary, Relonchem Ltd, received Marketing Authorisation from the UK MHRA for Baclofen 10 mg Tablets, a muscle relaxant used to treat spasms, cramping, and stiffness caused by multiple sclerosis or spinal injuries. Marksans, headquartered in Mumbai, operates manufacturing facilities in India, the USA, and the UK, all approved by major regulatory bodies, including the USFDA, UK MHRA, and Australian TGA. This approval follows Relonchem’s February authorisation for Ibuprofen and Paracetamol 200 mg/500 mg Film-coated Tablets, further expanding its portfolio in the UK market. Follow me for more such updates, Thank You!